Preanalytical Phase Conference

Join the preanalytical and laboratory medicine community

Providence Marriott Downtown
1 Orms St, Providence, RI 02904
Thursday, October 23 – Friday, October 24, 2025

Planning committee

Darci Block, PhD, DABCC (Chair) Mayo Clinic

Raffick Bowen, PhD, MHA, MLT (CSMLS), DClChem, DABCC, FCACB, FADLM Stanford University

Stacy Melanson, MD, PhD Brigham and Womens Hospital

Anna Merrill, PhD, DABCC University of Iowa

Faculty

• Sean Campbell, PhD, DABCC, FADLM | Sinai Health System, Toronto, ON
• Ria Fyffe-Freil, PhD | University of Nebraska Medical Center, Omaha, NE
• Mark Kellogg, PhD, MT(ASCP), DABCC | Boston Children's Hospital, Boston, MA
• Claire Knezevic, PhD, DABCC, NRCC, FADLM | Lurie Children’s Hospital of Chicago, Chicago, IL
• Tina Lockwood, PhD, DABMGG, DABCC | University of Washington, Seattle, WA
• Emily Ryan, PhD, DABCC | Advocate Clinical Laboratory, Macon, GA
• Frederick Strathmann, PhD, MBA, DABCC (CC, TC) | MOBILion Systems, Warrington, PA
• Nicole Tolan, PhD, DABCC | Washington University, St. Louis, MO
• Sarah Wheeler, PhD, FADLM, NRCC | University of Pittsburgh Medical Center, Pittsburgh, PA
• Melanie Yarbrough, PhD, DABMM, DABCC | Washington University, St. Louis, MO
• Mark A. Zaydman, MD, PhD | Washington University, St. Louis, MO

Target audience

This conference is designed to meet the needs of clinical laboratory physicians, supervisors, managers, and other laboratory professionals overseeing and/or carrying out preanalytical phase processes.

Learning level

This activity is designed to address participants at an intermediate level of instruction. Participants are expected to have some basic knowledge of the concepts and principles that will be presented.

Disclosures and statement of independence

The Association of Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following planners and faculty reported relevant financial relationship(s):

• Darci Block
  • Intellectual Property/Royalty Income: Elsevier
• Anna Merrill
  • Consultant Fee: Diagnostica Sago, Inc.
  • Advisory Board/Committee Membership: Diagnostica Stago, Inc.
• Mark A. Zaydman
  • Honorarium: Siemens, Sebia
  • Grant/Research Support: bioMerieux
• Melanie Yarbrough
  • Honorarium: BD
  • Consultant Fee: Beckman Coulter, BD, bioMerieux
  • Grant/Research Support: bioMerieux, Pattern Bioscience, Beckman Coulter
  • Advisory Board/Committee Membership: Shionogi
• Nicole Tolan
  • Consultant Fee: Health Advances
  • Advisory Board/Committee Membership: Abbott Diagnostics, Roche Diagnostics
• Sean Campbell
  • Honorarium: Sebia, Inc, Diagnostica Stago, Inc.
  • Grant/Research Support: Sebia, Inc.
  • Member, Scientific Advisory Board: Coagulation Sciences (minority equity stake)
• Mark Kellogg
  • Consultant Fee: Nexus Medical Labs LLC
• Emily Ryan
  • Consultant Fee: Sysmex, America
• Sarah Wheeler
  • Grant/Research Support: Siemens Healthineers

The following planners and faculty reported relevant financial relationship(s):

• Stacy Melanson
• Raffick Bowen
• Ria Fyffe-Freil
• Tina Lockwood
• Claire Knezevic
• Frederick Strathmann

All staff involved in the planning of this activity reported no financial relationships.

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Acknowledgement of sponsorship

This activity is supported by an educational grant from BD.

Accreditation statement

This activity will be submitted for 10.0 ACCENT® continuing education credits.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].

Ethical MedTech Compliance Approval

The 2025 ADLM Preanalytical Phase Conference has been approved as COMPLIANT by the EthicalMedTech Conference Vetting System (CVS). View Event Compliance

What is the EthicalMedTech Conference Vetting System (CVS)?

EthicalMedTech Conference Vetting System is an independent entity that reviews the compliance of third-party educational events with both MedTech Europe Code of Ethical Business Practice and Mecomed Code of Business Practice to determine the appropriateness for companies that are members of MedTech Europe and Mecomed to sponsor Healthcare Professionals to participate in conferences.

CVS aims to simplify and centralize decision-making for MedTech Europe and Mecomed members by establishing a single assessment procedure based on a set of criteria provisioned in the MedTech Europe Code of Ethical Business Practice. It also aims to harmonize the interpretation of the Code across the medical technology industry with the goals of greater consistency and transparency in industry behavior. Learn more: www.ethicalmedtech.eu